Table 2. Results of in situ hybridization, immunohistochemistry, and fluorescence in situ hybridization.
| Patient | Immunohistological subtype | ISH | Immunohistochemistry | FISH | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EBER | CD3 | CD5 | CD20 | CD10 | CD30 | BCL2 | BCL6 | MUM1 | CCND1 | Ki67(%) | MYC | MYC | ||||
| 1 | ND | + | − | − | + | − | +p | NA | NA | NA | NA | NA | − | − | ||
| 2 | non-GCB | + | − | − | + | − | +p | − | − | + | NA | 90 | + | − | ||
| 3 | non-GCB | − | − | − | + | − | − | + | − | + | − | 70 | + | − | ||
| 4 | non-GCB | − | − | − | + | − | − | + | + | + | − | 60 | − | − | ||
| 5 | non-GCB | + | − | − | + | − | + | + | − | NA | − | 80 | − | − | ||
| 6 | non-GCB | + | − | − | + | − | − | + | − | − | − | 65 | + | − | ||
| 7 | non-GCB | + | − | − | + | − | + | − | − | + | − | 90 | − | NA | ||
| 8 | non-GCB | + | − | NA | + | − | + | NA | − | + | NA | NA | + | − | ||
| 9 | non-GCB | + | − | − | + | − | +p | +p | − | + | NA | 80 | − | − | ||
| 10 | non-GCB | + | − | − | + | − | +p | +p | − | + | − | 80 | − | NA | ||
| 11 | non-GCB | +b | − | − | + | − | + | + | − | + | − | 75 | + | − | ||
| 12 | non-GCB | − | + | + | + | − | − | − | + | + | − | 70 | + | − | ||
| 13 | non-GCB | − | − | − | + | − | − | + | − | + | − | 60 | + | − | ||
+p partial positive and +b positive in background cells but not in tumor cells
ISH, in situ hybridization; FISH, fluorescent in situ hybridization; EBER, Epstein–Barr virus-encoding small RNA; CCND1, cyclin D1; GCB, germinal center B-cell; ND, not determined; NA, not available